Abstract
Germline de novo SETBP1 variants cause clinically distinct and heterogeneous neurodevelopmental disorders. Heterozygous missense variants at a hotspot encoding a canonical degron lead to SETBP1 accumulation and Schinzel-Giedion syndrome (SGS), a rare severe developmental disorder involving multisystem malformations. Heterozygous loss-of-function variants result in SETBP1 haploinsufficiency disorder which is phenotypically much milder than SGS. Following an initial description of four individuals with atypical SGS carrying heterozygous missense variants adjacent to the degron, a few individual cases of variants outside the degron were reported. Due to the lack of systematic investigation of genotype-phenotype associations of different types of SETBP1 variants, and limited understanding of the roles of the gene in brain development, the extent of clinical heterogeneity and how this relates to underlying pathophysiological mechanisms remain elusive, imposing challenges for diagnosis and patient care. Here, we present a comprehensive investigation of the largest cohort to-date of individuals carrying SETBP1 missense variants outside the degron (n=18, including one in-frame deletion). We performed thorough clinical and speech phenotyping with functional follow-up using cellular assays and transcriptomics. Our findings suggest that such variants cause a clinically and functionally variable developmental syndrome, showing only partial overlaps with classical SGS and SETBP1 haploinsufficiency disorder, and primarily characterised by intellectual disability, epilepsy, speech and motor impairment. We provide evidence of loss-of-function pathophysiological mechanisms impairing ubiquitination, DNA-binding and transcription. In contrast to SGS and SETBP1 haploinsufficiency, these effects are independent of protein abundance. Overall, our study provides important novel insights into diagnosis, patient care and aetiology of SETBP1-related disorders.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by the Max Planck Society (M.M.K.W., R.A.K., G.A., A.V., and S.E.F.). W.K.C was funded by SFARI and the JPB Foundation. M.S.H., I.E.S., and A.T.M. were funded by a National Health and Medical Research Council (NHMRC) Centre of Research Excellence Grant (1116976), an Australian Research Council (ARC) Discovery Project (DP120100285), an NHMRC Project Grant (1127144), and the March of Dimes Grant Scheme. M.S.H. was funded by an NHMRC Career Development Fellowship (1063799). I.E.S. was funded by an NHMRC Investigator Grant (1172897), an NHMRC Practitioner Fellowship (1006110), and NHMRC Development Grant (1153614). A.T.M. was funded by an NHMRC Investigator Grant (1195955), an NHMRC Practitioner Fellowship (1105008), and an NHMRC Development Grant (1153614). E.P. was supported by the National Health and Medical Research Council (GNT11149630), Australia and the research WGS was supported by NHMRC.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics committee/IRB of Commissie Mensgebonden Onderzoek Regio Arnhem-Nijmegen under number 2011/188 gave ethical approval for this work The Human Research Ethics Committee of The Royal Children's Hospital, Melbourne, Australia, approved study and testing on a research basis of proband 1 (Project 37353).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors
